155 related articles for article (PubMed ID: 37712717)
41. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
[TBL] [Abstract][Full Text] [Related]
42. EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada.
Sara Kuruvilla M; Liu G; Syed I; Gwadry-Sridhar F; Sheffield BS; Sachdeva R; Pencz A; Zhan L; Hueniken K; Patel D; Balaratnam K; Khan K; Grant B; Noy S; Singh K; Liu L; Rakibuz-Zaman M; Moldaver D; Kate Shanahan M; Cheema PK
Lung Cancer; 2022 Nov; 173():58-66. PubMed ID: 36152478
[TBL] [Abstract][Full Text] [Related]
43. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.
Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Piattoni S; Di Carlo L; Semeraro A; Darwish S; Tofanetti FR; Stocchi L; Mihaylova Z; Bellezza G; Del Sordo R; Daddi G; Crinò L; Tonato M
J Thorac Oncol; 2008 Apr; 3(4):365-73. PubMed ID: 18379354
[TBL] [Abstract][Full Text] [Related]
44. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.
Schiller JH; Adak S; Feins RH; Keller SM; Fry WA; Livingston RB; Hammond ME; Wolf B; Sabatini L; Jett J; Kohman L; Johnson DH
J Clin Oncol; 2001 Jan; 19(2):448-57. PubMed ID: 11208838
[TBL] [Abstract][Full Text] [Related]
45. Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC.
Jung HA; Lim J; Choi YL; Lee SH; Joung JG; Jeon YJ; Choi JW; Shin S; Cho JH; Kim HK; Choi YS; Zo JI; Shim YM; Park S; Sun JM; Ahn JS; Ahn MJ; Han J; Park WY; Kim J; Park K
Clin Cancer Res; 2022 Oct; 28(19):4312-4321. PubMed ID: 35838647
[TBL] [Abstract][Full Text] [Related]
46. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Roberts PJ; Stinchcombe TE; Der CJ; Socinski MA
J Clin Oncol; 2010 Nov; 28(31):4769-77. PubMed ID: 20921461
[TBL] [Abstract][Full Text] [Related]
47. Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report.
Fang C; Zhang C; Zhao WQ; Hu WW; Wu J; Ji M
BMC Med Genomics; 2019 Oct; 12(1):136. PubMed ID: 31619231
[TBL] [Abstract][Full Text] [Related]
48. Prognostic Impact of Central Nervous System Recurrence After Surgery in Patients With Epidermal Growth Factor Receptor Mutation-positive Non-small-cell Lung Cancer.
Okamoto T; Takenaka T; Yamazaki K; Hamatake M; Miura N; Takenoyama M; Kometani T; Ueda H; Kouso H; Yano T
Anticancer Res; 2023 Aug; 43(8):3543-3551. PubMed ID: 37500139
[TBL] [Abstract][Full Text] [Related]
49. Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC.
Saleh MM; Scheffler M; Merkelbach-Bruse S; Scheel AH; Ulmer B; Wolf J; Buettner R
J Thorac Oncol; 2022 Jan; 17(1):76-88. PubMed ID: 34601169
[TBL] [Abstract][Full Text] [Related]
50. Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901).
Li XM; Li WF; Lin JT; Yan HH; Tu HY; Chen HJ; Wang BC; Wang Z; Zhou Q; Zhang XC; Su J; Chen RL; Wu YL; Yang JJ
Clin Lung Cancer; 2021 Mar; 22(2):100-109.e3. PubMed ID: 33317922
[TBL] [Abstract][Full Text] [Related]
51. Post-Progression Survival Highly Influences Overall Survival in Driver Gene Mutation/Translocation Negative or Unknown Type of Non-Small Cell Lung Cancer.
Imai H; Onozato R; Kaira K; Kawashima S; Masubuchi K; Tajima K; Minato K
Oncology; 2022; 100(2):89-100. PubMed ID: 34844253
[TBL] [Abstract][Full Text] [Related]
52. Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis.
Bjaanæs MM; Fleischer T; Halvorsen AR; Daunay A; Busato F; Solberg S; Jørgensen L; Kure E; Edvardsen H; Børresen-Dale AL; Brustugun OT; Tost J; Kristensen V; Helland Å
Mol Oncol; 2016 Feb; 10(2):330-43. PubMed ID: 26601720
[TBL] [Abstract][Full Text] [Related]
53. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
[TBL] [Abstract][Full Text] [Related]
54. Prognostic Impact of Multiple Clinicopathologic Risk Factors and c-MET Overexpression in Patients Who Have Undergone Resection of Stage IB Non-Small-Cell Lung Cancer.
Kim IH; Lee IH; Lee JE; Hong SH; Kim TJ; Lee KY; Kim YK; Kim SJ; Sung SW; Park JK; Yoo IR; Kim YS; Kim JO; Kang JH
Clin Lung Cancer; 2016 Sep; 17(5):e31-e43. PubMed ID: 26992846
[TBL] [Abstract][Full Text] [Related]
55. Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer.
Geredeli C; Artac M; Yildirim S; Inal A; Dede I; Guler T; Boruban MC; Koral L; Karaagac M; Zamani AG; Altinok T; Aribas O; Bozcuk H; Demirkazik A
Tumour Biol; 2015 Jun; 36(6):4279-85. PubMed ID: 25596702
[TBL] [Abstract][Full Text] [Related]
56. Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study.
Sun H; Ren P; Chen Y; Lan L; Yan Z; Yang Y; Wang B; Wang C; Li Y; Li L; Zhang Y; Li Y; Wang Z; Pan Z; Jiang Z
BMC Cancer; 2023 Mar; 23(1):198. PubMed ID: 36864384
[TBL] [Abstract][Full Text] [Related]
57. Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations.
Ruiz-Cordero R; Ma J; Khanna A; Lyons G; Rinsurongkawong W; Bassett R; Guo M; Routbort MJ; Zhang J; Skoulidis F; Heymach J; Roarty EB; Tang Z; Medeiros LJ; Patel KP; Luthra R; Roy-Chowdhuri S
BMC Cancer; 2020 Jan; 20(1):83. PubMed ID: 32005111
[TBL] [Abstract][Full Text] [Related]
58. Prognostic value of mutant p53, Ki-67, and TTF-1 and their correlation with EGFR mutation in patients with non-small cell lung cancer.
Zhu WY; Hu XF; Fang KX; Kong QQ; Cui R; Li HF; He JY; Zhang YK; Le HB
Histol Histopathol; 2019 Nov; 34(11):1269-1278. PubMed ID: 31062864
[TBL] [Abstract][Full Text] [Related]
59. Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status.
Isaka T; Ito H; Yokose T; Saito H; Adachi H; Murakami K; Miura J; Kikunishi N; Rino Y
BMC Cancer; 2022 Sep; 22(1):966. PubMed ID: 36085020
[TBL] [Abstract][Full Text] [Related]
60. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]